Andrew Mallon

Andrew Mallon has extensive experience in the biotechnology industry, holding various roles in multiple companies. Andrew is currently working as the Chief Scientific Officer at a mid-stage biotechnology company since 2019. Prior to this, they served as the Chief Executive Officer at Trovex BioTherapeutics from 2018.

From 2013 to present, Mallon has been the CEO of Calista Therapeutics, where they focused on developing CFTR modulator therapeutics for Cystic Fibrosis and other programs in CNS and ophthalmology. Andrew also partnered with a strategic pharma company and discovered an effective oral treatment for CF.

Before that, Mallon was an Entrepreneur in Residence at a venture capital firm from 2017. Andrew'sresponsibilities included identifying and developing assets ready for mid-stage clinical trials and building management and advisory teams for successful investment and partnership models.

Mallon served as a board member for ChemoEnhanced LLC from 2009, focusing on the development of formulations for ceramide in rare forms of cancer. Andrew also held the position of Director at Maternova, Inc. from 2016.

In 2017, Mallon took a sabbatical from the biotechnology industry to become the Program Director at MassChallenge Rhode Island, supporting innovation and entrepreneurship. Andrew was also a board member at Prevallus Therapeutics, LLC from 2016 to 2017.

Mallon joined Luna Pharmaceuticals, Inc. in 2011 as a strategic advisor, working on the development of pill-free drink mix solutions for prenatal vitamins. Andrew previously served as the CEO of Ardane Therapeutics, Inc. from 2009 to 2013, focusing on the development of therapeutics for CNS disorders and ophthalmology.

Overall, Mallon's work experience demonstrates their expertise in biotechnology, leadership roles in startups and mid-stage companies, and their commitment to developing innovative therapeutics for various diseases.

Andrew Mallon obtained a Bachelor of Pharmacy with Honors degree from the University of Strathclyde from 1992 to 1998. Following that, they pursued further education and completed a degree in Registered Pharmacist from RPSGB in 1999. Subsequently, they enrolled at the University of Glasgow and obtained a Doctor of Philosophy (PhD) degree in Medicine, specializing in Neuropharmacology, from 2000 to 2005.

In terms of additional certifications, Andrew Mallon obtained a certification in GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) Course from CITI Program in February 2022.